Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer (eNRGy Trial)
Source: View publication →
In the phase 2 eNRGy trial, zenocutuzumab, a bispecific antibody targeting HER2 and HER3, demonstrated a 30% overall response rate with durable anti-tumor activity and a highly favorable safety profile across multiple solid tumors harboring rare NRG1 gene fusions.
Key Findings
Study Design
Study Limitations
Clinical Significance
The eNRGy trial establishes zenocutuzumab as a potent, tissue-agnostic targeted therapy for patients with solid tumors harboring NRG1 fusions, an aggressive and rare driver mutation with historically limited treatment options. By achieving a 30% ORR with a median response duration exceeding 11 months, alongside an exceptionally tolerable safety profile, the trial addresses a major unmet medical need and supports the routine integration of RNA-based next-generation sequencing to identify this rare oncogenic chimeric ligand. The data provided the clinical foundation for subsequent regulatory approvals for NRG1-positive NSCLC and pancreatic adenocarcinoma.
Historical Context
Neuregulin 1 (NRG1) fusions are rare but actionable oncogenic drivers found in less than 1% of solid tumors. Unlike classical chimeric receptors (e.g., ALK, ROS1), NRG1 fusions produce a chimeric ligand that binds avidly to human epidermal growth factor receptor 3 (HER3), inducing HER2-HER3 heterodimerization and unchecked downstream signaling. Historically, these patients exhibited poor responses to standard chemotherapy or immunotherapy, and prior multi-kinase inhibitors were ineffective. Zenocutuzumab introduced a first-in-class 'Dock & Block' mechanism—as a bispecific IgG1 antibody, it structurally targets both HER2 and HER3, specifically preventing the binding of the NRG1 fusion protein to HER3 and effectively neutralizing the fundamental oncogenic driver.
Guided Discussion
High-yield insights from every perspective
Zenocutuzumab is a bispecific antibody that binds both HER2 and HER3. Based on the molecular pathophysiology of NRG1 fusions, why is targeting both HER2 and HER3 necessary rather than using a single-target HER2 inhibitor like trastuzumab?
Key Response
NRG1 fusions produce a chimeric ligand that binds to HER3, causing obligatory HER2-HER3 heterodimerization and aberrant downstream PI3K/AKT/mTOR signaling. Zenocutuzumab uniquely blocks NRG1 binding to HER3 while simultaneously preventing HER2-HER3 heterodimerization via its dual-binding 'Dock and Block' mechanism. Traditional anti-HER2 therapies like trastuzumab only bind HER2 and do not efficiently block this ligand-dependent dimerization driven by the NRG1 fusion protein.
The eNRGy trial evaluated patients with various solid tumors harboring NRG1 fusions. In clinical practice, how should patients be screened for NRG1 fusions, and what does this imply for the diagnostic workflow of metastatic solid tumors?
Key Response
NRG1 fusions are rare (often under 1 percent) but occur across many tumor types, notably pancreatic cancer and non-small cell lung cancer (NSCLC). Given the tissue-agnostic efficacy of zenocutuzumab, residents must recognize the necessity of comprehensive next-generation sequencing (NGS). Crucially, DNA-based NGS often misses NRG1 fusions due to the presence of large intronic regions; therefore, incorporating RNA sequencing into the standard diagnostic workflow is essential to identify these actionable alterations.
Although zenocutuzumab shows a meaningful 30 percent ORR, a significant portion of patients have innate resistance or ultimately progress. What are the putative mechanisms of acquired resistance to HER2/HER3 bispecific antibodies in NRG1-fusion cancers, and how might future therapeutic sequencing address this?
Key Response
Resistance may arise through bypass track signaling such as MET amplification or EGFR mutations, downstream pathway activation like PIK3CA mutations, KRAS mutations, or PTEN loss, or secondary structural mutations in the HER2/HER3 kinase domains. Future strategies being investigated to address this resistance include combining zenocutuzumab with downstream pathway inhibitors (e.g., MEK or PI3K inhibitors) or utilizing HER3-directed antibody-drug conjugates (ADCs) like patritumab deruxtecan to deliver cytotoxic payloads directly to HER3-expressing cells.
With a 30 percent ORR in a heavily pretreated, tissue-agnostic population, zenocutuzumab offers a targeted option for a very rare genomic subset. How do we balance the cost and logistical burden of universal RNA-based NGS screening against the clinical benefit seen in these rare responders within community oncology practices?
Key Response
This question highlights the real-world challenge of precision oncology: the clinical utility of finding rare fusions is high for the individual, but the number needed to test (NNT) to find one mutation is massive. Attendings must advocate for standardized, cost-effective molecular tumor boards and institutional reflex testing protocols that utilize broad-panel RNA-based NGS upfront. This ensures rare variants are not missed, optimizing the balance between healthcare resource stewardship and delivering personalized, targeted interventions for patients out of standard options.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The eNRGy trial utilizes a tissue-agnostic, single-arm basket design. From a statistical and trial design perspective, what are the inherent limitations of using a pooled objective response rate as the primary endpoint across highly heterogeneous tumor histologies, and how can Bayesian hierarchical models improve the robustness of such trials?
Key Response
A pooled ORR assumes that the treatment effect is uniform across all tumor types, which is biologically implausible given differing baseline prognoses, tumor microenvironments, and co-mutational landscapes (e.g., NRG1-positive pancreatic cancer versus NSCLC). Bayesian hierarchical models address this by allowing for the borrowing of information across different tumor cohorts while still explicitly modeling and accounting for inter-cohort heterogeneity. This provides a statistically robust, histology-specific estimation of efficacy, which is critical for interpreting basket trials in rare genomic subsets.
As an editor evaluating the eNRGy trial for publication, how do you critically appraise the validity of a single-arm trial for a rare biomarker, specifically concerning the lack of a randomized control arm and the potential for prognostic confounding in the enrolled patient population?
Key Response
Without a randomized control arm, it is challenging to distinguish a true therapeutic effect from the potentially indolent natural history of some NRG1-fusion tumors. A rigorous peer reviewer would scrutinize the study for robust independent central review of radiographic responses, the utilization of synthetic or historical control arms for context, and transparent reporting of prior treatment lines and time-to-progression on prior therapies. This ensures the 30 percent ORR is genuinely attributable to zenocutuzumab rather than selection bias favoring patients with slower-growing disease.
Based on the eNRGy trial demonstrating a 30 percent ORR, what level of evidence does this provide for including zenocutuzumab in tissue-agnostic guidelines, and how does this evidentiary threshold compare to other tumor-agnostic approvals like larotrectinib for NTRK fusions in NCCN or ESMO frameworks?
Key Response
NCCN currently recommends broad molecular profiling for many solid tumors. While a 30 percent ORR is modest compared to the >75 percent ORR seen with larotrectinib in NTRK fusions, the lack of effective alternatives for NRG1 fusions justifies an NCCN Category 2A recommendation for zenocutuzumab in advanced disease post-standard therapy. Guideline committees must weigh this lower response rate against the high unmet clinical need, the durable nature of the responses, and the favorable toxicity profile when formalizing its inclusion as a preferred biomarker-directed treatment option in clinical pathways.
Clinical Landscape
Noteworthy Related Trials
NAVIGATE Trial
Tested
Larotrectinib 100mg BID
Population
Patients with TRK fusion-positive solid tumors
Comparator
None (Single-arm)
Endpoint
Objective Response Rate (ORR)
LIBRETTO-001 Trial
Tested
Selpercatinib 160mg BID
Population
Patients with RET fusion-positive NSCLC and RET-mutant thyroid cancers
Comparator
None (Single-arm)
Endpoint
Objective Response Rate (ORR)
DESTINY-PanTumor02 Trial
Tested
Trastuzumab deruxtecan 5.4 mg/kg
Population
Patients with HER2-expressing advanced solid tumors
Comparator
None (Single-arm)
Endpoint
Objective Response Rate (ORR)
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis